How long should heparin (Heparin Sodium) gtt (intravenous infusion) be held for a patient with a significantly elevated Partial Thromboplastin Time (PTT) of 155?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Significantly Elevated PTT (155) on Heparin Infusion

For a PTT of 155 seconds on heparin infusion, hold the heparin for 1-2 hours and recheck the PTT before resuming at a reduced rate. 1

Immediate Actions

  • Stop the heparin infusion immediately when the PTT is this significantly elevated (155 seconds, which is well above the therapeutic target of 1.5-2.5 times control or approximately 60-80 seconds). 1

  • Do not administer protamine sulfate for supratherapeutic PTT values in the absence of active bleeding, as the heparin will clear naturally and protamine carries its own risks. 1

  • Assess the patient for bleeding complications, as PTT values >70 seconds are associated with higher likelihood of bleeding, though bleeding during heparin therapy is generally infrequent unless invasive procedures are performed or local lesions exist. 1

Duration of Hold and Monitoring

  • Hold heparin for 1-2 hours for a PTT of 155 seconds, as this allows sufficient time for the anticoagulant effect to diminish given heparin's short half-life of approximately 60-90 minutes. 1, 2

  • Recheck PTT after 1-2 hours to confirm the value has decreased toward the therapeutic range before restarting the infusion. 1

  • Resume heparin at a reduced infusion rate (typically decrease by 2-3 units/kg/hour or 200-300 units/hour depending on your institution's protocol) once the PTT falls below 100 seconds. 1

  • Recheck PTT 4-6 hours after restarting the infusion to ensure therapeutic levels are achieved without overshooting again. 1

Key Monitoring Principles

  • The therapeutic target aPTT ratio should be 1.5-2.5 times the control value, corresponding to anti-Xa activity of 0.3-0.6 IU/mL. 1

  • PTT values should not exceed 100 seconds to minimize bleeding risk while maintaining therapeutic anticoagulation. 1

  • The relationship between excessive PTT prolongation and bleeding complications is well-established, making prompt dose adjustment critical. 1

Common Pitfalls to Avoid

  • Do not simply reduce the infusion rate without holding the heparin first when the PTT is this elevated, as the anticoagulant effect needs time to diminish. 1

  • Do not restart at the same infusion rate that caused the excessive prolongation—always reduce the rate by at least 2-3 units/kg/hour. 1

  • Avoid holding heparin for excessive periods (>4 hours) in patients with acute thromboembolism, as this increases the risk of recurrent thrombotic events. 3

  • Check for heparin resistance factors if PTT remains difficult to control, including increased binding to plasma proteins, which may require anti-Xa level monitoring instead. 1

  • Monitor platelet counts every 2 days during heparin therapy to detect heparin-induced thrombocytopenia, particularly between days 4-14 of treatment. 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Recommended Interval for Clamping Heparin Before Accessing the Same Site

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The management of heparin-induced thrombocytopenia.

British journal of haematology, 2006

Research

Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.

Hematology. American Society of Hematology. Education Program, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.